Primary medical therapy for BRAF^V600E-mutant melanoma brain metastases-is this good enough? - Authors' reply

Affiliations

¹ Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: mdavies@mdanderson.org.
² Service de Dermatologie Générale et Oncologique, Hôpital A Paré, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, France.
³ Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.

Comment

Michael A Davies et al. Lancet Oncol. 2017 Sep.

. 2017 Sep;18(9):e509.

doi: 10.1016/S1470-2045(17)30640-X.

¹ Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: mdavies@mdanderson.org.
² Service de Dermatologie Générale et Oncologique, Hôpital A Paré, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, France.
³ Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.

No abstract available

Comment on

Dabrafenib plus trametinib in patients with BRAF^V600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV. Davies MA, et al. Lancet Oncol. 2017 Jul;18(7):863-873. doi: 10.1016/S1470-2045(17)30429-1. Epub 2017 Jun 4. Lancet Oncol. 2017. PMID: 28592387 Free PMC article. Clinical Trial.
Primary medical therapy for BRAF^V600E-mutant melanoma brain metastases-is this good enough?
Kruser TJ, Vogelbaum MA. Kruser TJ, et al. Lancet Oncol. 2017 Sep;18(9):e508. doi: 10.1016/S1470-2045(17)30633-2. Lancet Oncol. 2017. PMID: 28884696 No abstract available.